Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isotonic short-peptide enteral nutrition emulsion is a specialized medical nutrition product designed for patients with impaired digestive and/or absorptive function who cannot tolerate whole protein or large-molecule nutrient formulas. The formulation uses pre-digested peptides (short peptides) as the primary nitrogen source, along with carbohydrates and medium-chain triglycerides (MCTs), to enhance absorption and reduce gastrointestinal burden. It is isotonic (approximately 300 mOsm/L), which improves gastrointestinal tolerance compared to hypertonic formulations and reduces the risk of diarrhea and gastric retention. This product is indicated for conditions such as short bowel syndrome, pancreatic insufficiency, chronic inflammatory bowel disease, chemotherapy/radiation-induced enteritis, critically ill patients, or those transitioning from parenteral to enteral nutrition. It can be used as complete or supplemental enteral nutrition via oral intake or tube feeding[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on isotonic short-peptide enteral nutrition emulsion.